Altimmune Inc (NASDAQ: ALT)’s stock price has dropped by -8.07 in relation to previous closing price of 6.01. Nevertheless, the company has seen a gain of 9.84% in its stock price over the last five trading days. accessnewswire.com reported 2025-05-13 that Reports third consecutive record quarter for Fintech segment Mswipe acquisition, expected to close early in Q2, will be immediately accretive upon close to revenue and EBITDA Payment Card offering, already integrated with ALT5 Pay, to be immediately made available to existing 1000+ ALT Customers- LAS VEGAS, NEVADA / ACCESS Newswire / May 13, 2025 / ALT5 Sigma Corporation (the “Company” or “ALT5”) (NASDAQ:ALTS)(FRA:5AR1), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, is pleased to announce its financial highlights for the fiscal first quarter ended March 29, 2025, along with the execution of definitive agreements to acquire Mswipe (www.mswipe.ca). Mswipe is a next-generation payment solutions provider offering multi-currency, fiat payment card services, along with crypto-enabled capabilities through its existing integration with the ALT5 platform.
Is It Worth Investing in Altimmune Inc (NASDAQ: ALT) Right Now?
ALT has 36-month beta value of 0.62. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ALT is 76.21M, and currently, short sellers hold a 29.63% ratio of that float. The average trading volume of ALT on May 13, 2025 was 2.60M shares.
ALT’s Market Performance
ALT stock saw an increase of 9.84% in the past week, with a monthly gain of 25.28% and a quarterly increase of -12.16%. The volatility ratio for the week is 8.15%, and the volatility levels for the last 30 days are 7.06% for Altimmune Inc (ALT). The simple moving average for the past 20 days is 6.84% for ALT’s stock, with a -16.49% simple moving average for the past 200 days.
Analysts’ Opinion of ALT
Stifel, on the other hand, stated in their research note that they expect to see ALT reach a price target of $18. The rating they have provided for ALT stocks is “Buy” according to the report published on January 08th, 2025.
UBS gave a rating of “Buy” to ALT, setting the target price at $26 in the report published on November 12th of the previous year.
ALT Trading at 6.51% from the 50-Day Moving Average
After a stumble in the market that brought ALT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.49% of loss for the given period.
Volatility was left at 7.06%, however, over the last 30 days, the volatility rate increased by 8.15%, as shares surge +20.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.93% lower at present.
During the last 5 trading sessions, ALT rose by +10.83%, which changed the moving average for the period of 200-days by -16.67% in comparison to the 20-day moving average, which settled at $5.17. In addition, Altimmune Inc saw -23.37% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALT starting from Sohn Catherine A., who purchase 1,000 shares at the price of $5.78 back on Mar 17 ’25. After this action, Sohn Catherine A. now owns 1,000 shares of Altimmune Inc, valued at $5,784 using the latest closing price.
WEAVER GREGORY L, the Chief Financial Officer of Altimmune Inc, purchase 10,000 shares at $5.20 during a trade that took place back on Mar 13 ’25, which means that WEAVER GREGORY L is holding 10,000 shares at $51,996 based on the most recent closing price.
Stock Fundamentals for ALT
Current profitability levels for the company are sitting at:
- -5158.6 for the present operating margin
- -9.05 for the gross margin
The net margin for Altimmune Inc stands at -4752.95. The total capital return value is set at -0.8. Equity return is now at value -59.86, with -54.33 for asset returns.
Based on Altimmune Inc (ALT), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -47.5. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -11463.56.
Currently, EBITDA for the company is -94.81 million with net debt to EBITDA at 0.37. When we switch over and look at the enterprise to sales, we see a ratio of 19628.31. The receivables turnover for the company is 0.01for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.10.
Conclusion
To put it simply, Altimmune Inc (ALT) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
